|
1. BIOLOGIE
|
|
|
|
1.1 BIOLOGIE - GÉNOME
|
|
|
Breast cancer: altered chromosomes lead to treatment resistance [DKFZ]
|
|
|
|
|
|
"The trick involving activating and then turning off genes allowed us to simulate targeted cancer treatment. Chromosome instability acts as a driver of genetic variability that confers a survival advantage through resistance development on the cancer cells under the treatment-related selection pressure."
|
|
|
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
'Electronic nose' sniffs out condition that can lead to cancer [NHS Choices]
|
|
|
|
|
|
This was a group of people who were more likely to have Barrett's oesophagus, and studies in such samples often give better test results. We do not know whether breath testing a wider group of people in the general population would also identify people with Barrett's oesophagus to the same degree of accuracy.
|
|
|
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
4.15 DÉP., DIAG. & PRONO. - IMAGERIE
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
MGI Deconstructs the Sequencer [Omics! Omics!]
|
|
|
|
|
|
Tx isn't a specific instrument but a concept which can be realized in many ways. MGI sees it as a custom solution which will be optimized for each customer. It operates in a standard laboratory environment; no need for a clean room or extra sophisticated control of ambient temperature.
|
|
|
|
|
|
|
|
|
5. TRAITEMENTS
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
|
5.12.4 IMMUNOTHÉRAPIES - ESSAIS
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.1 PHARMA - PARTENARIATS
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
|
Polivy struck by NICE ‘no’ [Pharma Times]
|
|
|
|
|
|
The National Institute for Health and Care Excellence (NICE) has announced that it does not recommend Polivy (polatuzumab), Roche’s treatment for adults with diffuse large B-cell lymphoma (DLBCL).
|
|
|
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
Growing old with cancer [UICC]
|
|
|
|
|
|
Ageing is a known risk factor for cancer and currently, 60% of people who have cancer are aged 65 and over. This figure is expected to double over the next two decades. UICC is partnering with Sanofi to help address the challenges of ageing with cancer.
|
|
|
|
|
|
|
6.6 PUBLICATIONS, POLITIQUES SCIENTIFIQUES
|
|
|
An Open Agenda: European Funder Approaches to Open Science [The Scholarly Kitchen]
|
|
|
|
|
|
Funders could do even more to ensure their own practice matches their policy aspirations. This means investing in open scholarly communication infrastructure, scrutinizing publishing expenditure, including open criteria more in evaluation processes, and becoming active signatories and proponents of initiatives designed to promote responsible use of metrics, such as DORA, the Leiden Manifesto, and the TOP guidelines.
|
|
|
|
|
|